Relapsing Remitting Multiple Sclerosis News and Research

RSS

Biogen Idec's revenue increases 51% to $2.1 billion in first quarter 2014

Biogen Idec Inc. today reported first quarter 2014 results, including revenue of $2.1 billion, a 51% increase compared to the first quarter of 2013.

23 Apr 2014

U.S. Supreme Court agrees to hear Teva Pharmaceutical's appeal related to COPAXONE patent

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced that the U.S. Supreme Court has granted the Company's COPAXONE® certiorari petition and will hear its appeal of a decision from the United States Court of Appeals for the Federal Circuit that invalidated the claim of U.S. Patent 5,800,808 (the "'808 patent").

1 Apr 2014

Elevated body temperature linked to fatigue in relapsing-remitting multiple sclerosis

Kessler Foundation researchers have demonstrated for the first time ever that body temperature is elevated endogenously in relapsing-remitting multiple sclerosis (RRMS) and linked to worse fatigue. The article was published ahead of print on Feb. 21, 2014 in Archives of Physical Medicine & Rehabilitation. Sumowski J, Leavitt V: Body temperature is elevated and linked to fatigue in relapsing-remitting multiple sclerosis, even without heat exposure.

19 Mar 2014

Scientists map key elements of immune overreaction triggered by influenza virus infection

Scientists at The Scripps Research Institute (TSRI) have mapped key elements of a severe immune overreaction—a "cytokine storm"—that can both sicken and kill patients who are infected with certain strains of flu virus.

3 Mar 2014

TSRI scientists describe severe immune overreaction caused by flu infections

Scientists at The Scripps Research Institute have mapped key elements of a severe immune overreaction—a “cytokine storm”—that can both sicken and kill patients who are infected with certain strains of flu virus.

28 Feb 2014

Study shows how immune system reconstitutes itself following immune-depleting therapy

A new study describes the complexity of the new T cell repertoire following immune-depleting therapy to treat multiple sclerosis, improving our understanding of immune tolerance and clinical outcomes.

18 Feb 2014

Active Biotech, Teva remain committed to NERVENTRA clinical development program for multiple sclerosis

Teva Pharmaceutical Industries Ltd. and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that both companies remain committed to the NERVENTRA® (laquinimod) clinical development program for multiple sclerosis (MS) following the announcement of a negative opinion for the treatment of relapsing-remitting multiple sclerosis (RRMS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

27 Jan 2014

IQWiG study finds no added benefit of teriflunomide

Teriflunomide (trade name: Aubagio) has been approved in Germany since August 2013 for adults with relapsing remitting multiple sclerosis. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products, the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new drug offers an added benefit over the appropriate comparator therapy specified by the Federal Joint Committee (G-BA).

8 Jan 2014

Health Canada approves Genzyme's Lemtrada for adults with relapsing remitting multiple sclerosis

Genzyme, a Sanofi company, announced today that Health Canada has approved Lemtrada (alemtuzumab) for the management of adult patients with relapsing remitting multiple sclerosis, with active disease defined by clinical and imaging features, who have had an inadequate response to interferon beta or other disease-modifying therapies.

13 Dec 2013

Takeda and Teva announce agreement related to commercialization of glatiramer acetate in Japan

Teva Pharmaceutical Industries Ltd. and Takeda Pharmaceutical Company Limited (Takeda) today announced the signing earlier this year of an agreement in which Teva licensed to Takeda the right to commercialize Teva's innovative glatiramer acetate ( active ingredient) formulation for the treatment of multiple sclerosis, in Japan.

4 Dec 2013

New data show positive results from Phase 4 study of Avonex Pen for treatment of RRMS patients

New data presented at the 6th Pan Asian Committee for Treatment and Research in Multiple Sclerosis, show positive preliminary results from PERSIST, a 12-month, Phase 4 clinical study of once weekly Avonex Pen for patients with relapsing-remitting multiple sclerosis.

13 Nov 2013

Revalesio to conduct RNS60 Phase IIa clinical trial in RRMS patients

Revalesio Corporation is pleased to announce a new collaboration with noted neurologist Dr. Roland Martin, Head of Neuroimmunology and MS Research at the Department of Neurology, University Hospital Zurich. Dr. Martin will be conducting a Phase IIa clinical trial of RNS60 in patients with relapsing-remitting multiple sclerosis.

12 Nov 2013

Biogen Idec Q3 total revenues increase 32% to $1.8 billion

Biogen Idec Inc. today reported third quarter 2013 total revenues of $1.8 billion, an increase of 32% over the third quarter of 2012. Non-GAAP diluted EPS for the third quarter of 2013 were $2.35, an increase of 23% over the third quarter of 2012.

28 Oct 2013

Study reveals gray matter atrophy in multiple sclerosis correlated with emotional decline

In multiple sclerosis, gray matter atrophy is extensive, and cognitive deficits and mood disorders are frequently encountered. It has been conjectured that focal atrophy is associated with emotional decline.

12 Aug 2013

EMA's CHMP issues positive opinion for approval of Genzyme's LEMTRADA in Europe

Genzyme, a Sanofi company, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for approval of LEMTRADA (alemtuzumab) for the treatment of adult patients with relapsing remitting multiple sclerosis with active disease defined by clinical or imaging features.

28 Jun 2013

Study shows absence of gene leads to early onset of more serious disease in MS animal model

Scientists led by a UCSF neurology researcher are reporting that they have identified the likely genetic mechanism that causes some patients with multiple sclerosis (MS) to quickly progress to a debilitating stage of the disease while other patients progress much more slowly.

25 Jun 2013

Study examines link between IL-17F and treatment response to interferon beta-1b in multiple sclerosis patients

A study by Hans-Peter Hartung, M.D., of Heinrich-Heine-Universität, Düsseldoft, Germany, and colleagues examines the association between IL-17F and treatment response to interferon beta-1b among patients with relapsing-remitting multiple sclerosis.

4 Jun 2013

FDA accepts Teva Pharmaceutical's sNDA for COPAXONE

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has accepted for review the company's supplemental new drug application for COPAXONE (glatiramer acetate injection) 40mg/ 1mL, a higher concentration dose of COPAXONE that offers a less frequent three times a week dosing regimen administered subcutaneously for patients with relapsing-remitting multiple sclerosis.

31 May 2013

Natalizumab may be second-line option for pediatric MS patients

Natalizumab may be an effective and well tolerated second-line treatment for pediatric patients with highly active relapsing-remitting multiple sclerosis, say researchers.

26 Feb 2013

Positive top-line results from Biogen Idec’s peginterferon beta-1a Phase 3 trial on RRMS

Today Biogen Idec released the primary efficacy analysis and safety data from its Phase 3 pivotal clinical trial, ADVANCE.

28 Jan 2013